Summary:
A large systematic review and meta-analysis of nearly 16 million people across three continents found that individuals diagnosed with attention‑deficit/hyperactivity disorder (ADHD) face substantially higher mortality risk than those without the diagnosis. Overall mortality was about 70% higher among people with ADHD. Elevated risk was driven by higher rates of suicide, accidental and intentional injuries, and deaths from natural causes such as cardiovascular and metabolic disease. Preliminary data from a subset of studies also suggest that treatment with prescribed ADHD medications is linked to a roughly 25% reduction in all‑cause mortality.
Key Facts:
- 70% Higher All‑Cause Mortality: Pooled results from 19 longitudinal cohort studies with follow‑up periods up to 20 years found an overall hazard ratio (HR) of 1.71 for all‑cause mortality in people with ADHD compared with controls.
- Major Drivers of Risk: Cause‑specific mortality was elevated across several categories: suicide (about 90% higher), unintentional or intentional injuries (about 55% higher), and natural‑cause deaths including cardiovascular disease and metabolic conditions (about 27% higher).
- Medication Appears Protective: In the three studies that reported medication status, ADHD medication use was associated with a 25% lower risk of death from any cause (HR ≈ 0.75), indicating a potential protective effect that warrants further investigation.
Source: University College London (UCL) / University of Liverpool
Overview
Attention‑deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition characterized by difficulties with attention, impulse control, and executive functioning. Beyond its well‑known cognitive and educational impacts, mounting epidemiological evidence highlights important consequences for long‑term health and survival. This systematic review and meta‑analysis, published in JAMA Network Open, pooled data from 19 cohort studies that together included 15,920,970 participants and spanned multiple countries and age ranges, with some cohorts followed for more than 20 years.
Mapping the Causes of Premature Mortality
The elevated mortality observed in people with ADHD reflects a mixture of behavioral, psychiatric, and physical health factors. Key cause‑specific findings include:
- Suicide (≈90% increase): Suicide rates were markedly higher among individuals with ADHD, which likely reflects higher prevalence of comorbid depression, emotional dysregulation, and impulsive decision‑making during crises.
- Injuries (≈55% increase): Deaths from intentional and unintentional injuries—such as road traffic accidents, falls, and other fatal accidents—were elevated, plausibly linked to inattention, distractibility, and greater risk‑taking behavior.
- Natural Causes (≈27% increase): Mortality from medical conditions, including cardiovascular disease, type 2 diabetes, metabolic syndrome, and cancer, was also higher in people with ADHD. Contributing factors likely include higher rates of tobacco, alcohol or substance use, lifestyle risks, and barriers to consistent healthcare engagement and chronic disease management.
Senior author Joshua Stott, PhD, of UCL Psychology and Language Sciences notes that these results add depth to earlier findings about reduced life expectancy in ADHD by identifying multiple causes that contribute to that gap. The researchers emphasize that many of the drivers are modifiable and related to healthcare access, lifestyle, and psychiatric comorbidity.
The Protective Potential of Pharmacotherapy
A noteworthy signal in the review was the association between ADHD medication use and lower mortality. Across the three studies that recorded medication exposure, treatment with prescribed ADHD medication was associated with an estimated 25% reduction in all‑cause mortality compared with untreated peers. The authors stress that this finding is promising but preliminary and should be interpreted cautiously since only a small number of studies included medication data and heterogeneity across studies was substantial.
First author Lucy Corrigan of the University of Liverpool highlights that medication may play an important role in improving health outcomes for people with ADHD, but it is just one component of comprehensive, long‑term care that often includes psychosocial supports and chronic disease management.
Closing the Diagnostic and Treatment Gap
The investigators stress that ADHD itself is not intrinsically fatal. Rather, the increased mortality appears to reflect a combination of untreated symptoms, coexisting mental and physical health conditions, lifestyle risks, and systemic barriers to care. Timely and accurate diagnosis, improved access to evidence‑based assessment and treatment, and efforts to reduce healthcare inequities are critical to narrowing the mortality gap.
Stott and coauthors recommend prioritizing equitable access to assessment and sustained treatment—especially for older adults who may be underdiagnosed—alongside public health strategies to address substance use, mental health comorbidity, and engagement with preventive medical care.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed for this summary.
- Additional explanatory context was added by editorial staff.
About this ADHD Research:
- Media Contact: Alexandra Middleton
- Source: UCL
- Image Credit: Image credited to Neuroscience News
- Original Research (Open Access): JAMA Network Open (Oct 19, 2026). “Mortality among people with attention‑deficit/hyperactivity disorder: A systematic review and meta‑analysis.” Authors: Lucy Corrigan, BSc; Lauren Heywood, MSc; Gavin R. Stewart, PhD; Elizabeth O’Nions, PhD; Henry Shelford, MSc; Joshua Stott, PhD; and Amber John, PhD.
- DOI: 10.1001/jamanetworkopen.2026.39448
Abstract
Mortality among people with attention‑deficit/hyperactivity disorder: A systematic review and meta‑analysis
Importance
ADHD is linked to adverse life outcomes and increased mortality. Clarifying the scale of mortality risk using international data and examining the potential association between medication and mortality are essential for clinical practice and public health planning.
Objectives
To quantify associations between ADHD and all‑cause and cause‑specific mortality, and to evaluate whether mortality risk differs by ADHD medication use.
Data Sources
Systematic searches of PubMed, Web of Science, PsycINFO, EMBASE, MEDLINE, and CINAHL were performed from database inception to July 8, 2025.
Study Selection
Included studies were quantitative cohorts reporting all‑cause or cause‑specific mortality in people with ADHD, defined by diagnostic criteria, self‑report, trait measures, or polygenic risk scores. Nonoriginal research, qualitative reports, non–peer‑reviewed work, and studies without mortality outcomes were excluded.
Data Extraction and Synthesis
Two reviewers independently extracted data, with study quality assessed by one reviewer. Pooled hazard ratios were calculated using random‑effects meta‑analysis.
Main Outcomes and Measures
Primary outcomes were all‑cause mortality and cause‑specific mortality (suicide, unintentional or intentional injury, and natural causes), reported as HRs with 95% confidence intervals.
Results
Nineteen studies including 15,920,970 participants (36.1% female) were analyzed. ADHD was associated with increased all‑cause mortality (HR, 1.71; 95% CI, 1.31–2.24; P < .001). Significant associations were also observed for suicide (HR, 1.89), injury (HR, 1.55), and natural causes (HR, 1.27). ADHD medication use was associated with reduced all‑cause mortality (HR, 0.75), though substantial heterogeneity existed across studies.
Conclusions and Relevance
This meta‑analysis indicates that ADHD is linked to elevated mortality across multiple causes, and that medication use may be associated with lower all‑cause mortality. The findings highlight the need for timely diagnosis, comprehensive treatment, and strategies to address healthcare inequities, while acknowledging heterogeneity and the need for standardized research methods to better define risk.
